Amgen

Amgen provides testimony to FDA stakeholder hearing on biosimilars

Monday, May 14, 2012 01:40 PM

Joseph P. Miletich, M.D., Ph.D., senior vice president of R&D at Amgen, submitted testimony to the FDA stakeholder hearing on biosimilars, urging members of the FDA panel charged with implementing a pathway for biosimilars to establish approval standards that advance patient safety and promote confidence in biosimilars marketed in the U.S.

More... »


PRA, Amgen collaborate on biosimilar development program

Wednesday, May 2, 2012 09:18 AM

PRA, a global CRO, has formed a strategic relationship with biotech Amgen for a series of phase III studies to develop several biosimilar drugs on a worldwide basis.

More... »


Amgen to acquire Mustafa Nevzat of Turkey

Wednesday, April 25, 2012 10:22 AM

Amgen, a global biotech based in Thousand Oaks, Calif., will acquire 95.6% of shares in Mustafa Nevzat Pharmaceuticals (MN), a privately held Turkish pharmaceutical company, for approximately $700 million. The all-cash transaction will significantly expand Amgen's presence in Turkey and the surrounding region, which are large, fast-growing, priority markets for Amgen.  

More... »

Amgen to acquire KAI Pharmaceuticals

Tuesday, April 10, 2012 11:21 AM

Amgen of Thousand Oaks, Calif., has agreed to acquire South San Francisco-based KAI Pharmaceuticals, a privately held pharmaceutical company.  KAI's lead product candidate, KAI-4169, is a novel agent being initially studied for the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD) who are on dialysis. Amgen will acquire worldwide rights, excluding Japan, to KAI-4169.

More... »

UCB, Amgen begin phase III postmenopausal osteoporosis program

Friday, April 6, 2012 03:47 PM

UCB, a global biopharmaceutical based in Brussels, Belgium, and biotech Amgen have initiated their sclerostin antibody (CDP7851/AMG785) phase III clinical trial program for the treatment of postmenopausal osteoporosis.

More... »

Amgen, AstraZeneca to develop and commercialize inflammation portfolio

Monday, April 2, 2012 04:38 PM

Amgen and AstraZeneca have agreed to jointly develop and commercialize five monoclonal antibodies from Amgen's clinical inflammation portfolio (AMG 139, AMG 157, AMG 181, AMG 557 and brodalumab (AMG 827)).

More... »

EntreMed names two to board of directors

Tuesday, February 7, 2012 01:07 PM

EntreMed, a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, has appointed Wei-Wu He, Ph.D, executive chairman of its board of directors, and Tak W. Mak, Ph.D, as member of the board of directors.

More... »

Amgen to Acquire Micromet

Thursday, January 26, 2012 10:53 AM

Amgen, of Thousand Oaks, Calif., will acquire Rockville, Md.-based Micromet for $11 per share in cash, or approximately $1.16 billion. The deal was unanimously approved by both the Amgen and Micromet boards of directors.

More... »

Amgen, Watson collaborate to develop oncology biosimiliars

Tuesday, December 20, 2011 12:44 PM

Amgen and Watson Pharmaceuticals will collaborate to develop and commercialize several oncology antibody biosimilar medicines.

More... »

Mirani joins DaVita Labs

Thursday, December 1, 2011 10:43 AM
DaVita Labs has named Leslie Mirani vice president and general manager. 

More... »


CWWeekly

May 21

Parexel consultant testifies on FDA biosimilars guidance

Global Telecom Testing checks worldwide toll-free phone lines for multinational clinical trials

To read the full articles for this issue of CWWeekly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

CWWeekly

May

Newer sites most optimistic about the future
Investigative sites of all sizes, from part-time physician-run sites to large dedicated research centers, report a rebound in operating conditions, according to a new CenterWatch analysis, yet sites from each subgroup indicate they have concerns…

Risk-based monitoring slow to catch on with industry
It's estimated that the cost of physically sending monitors to all investigative sites at regular intervals, a model the industry itself developed and has adhered to for about a decade, eats up one-third to one-half of…

Eye On Millennium
Millennium, The Takeda Oncology Company, discovers and develops novel treatments applying world-class recombinant technology to a wide variety of oncology disease targets…

To read the full articles for this issue of The CenterWatch Monthly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

JobWatch centerwatch.com/jobwatch

Featured Jobs